Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We used CRISPR-DS to deeply sequence (mean Duplex depth ~3000×) the TP53 gene in 30 Pap tests from 21 women without cancer and 9 women with serous ovarian carcinoma with known TP53 driver mutations.
|
31839337 |
2020 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recently, this category of ovarian carcinoma has gained increasing attention owing to the recognition of morphological varieties of TP53-mutated high-grade ovarian carcinoma.
|
30636633 |
2019 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
|
30887755 |
2019 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Targeted Genomic Sequencing Reveals Novel <i>TP53</i> In-frame Deletion Mutations Leading to p53 Overexpression in High-grade Serous Tubo-ovarian Carcinoma.
|
31177126 |
2019 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
CA125 and p53 are reliable markers that are useful for differentiating both uterine serous and ovarian serous carcinoma from their most common subtypes (endometrioid type carcinoma of ovary and uterus) but so far there is no histopathologic marker that differentiates USC from OSC.
|
31165997 |
2019 |
Ovarian Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
p53 inhibitor can increase the growth rate of subcutaneously transplanted tumor in nude mice. p53 inhibitor could decrease the expression of p53 and p21 at both mRNA and protein levels and increase the expression of MDM2 at both mRNA and protein levels in ovarian carcinoma transplanted subcutaneously in nude mice.
|
29565482 |
2018 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
High-grade serous ovarian carcinoma is characterised by TP53 mutations, DNA repair defects, and genomic instability.
|
29361470 |
2018 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our NGS study of BM of ovarian carcinoma revealed a significant number of BRCA-mutations beside TP53, ATM and CHEK2 mutations.
|
28497333 |
2017 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
|
26847329 |
2016 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.
|
27997533 |
2016 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In conclusion, changes in O-GlcNAc homeostasis activate the wild type p53 pathway in ovarian cancer cells, and OGA inhibition has the potential as an adjuvant treatment for ovarian carcinoma.
|
27402830 |
2016 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We demonstrated that in a unique population of HGSOC cancer cells with cancer stem cell properties, p53 protein aggregation is associated with p53 inactivation and platinum resistance.
|
25263447 |
2015 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Human OCCs harboring different TP53 HSMs were selectively resistant to microtubule stabilizers.
|
25958320 |
2015 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
|
26620706 |
2015 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our findings indicate that the adverse prognosis associated with TP53 and PIK3CA mutations in human cancers can be functionally replicated in mouse models of type I→type II OvCA progression.
|
23499052 |
2013 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The objective of this study is to investigate whether wild-type TP53 status in high-grade serous ovarian carcinoma is associated with poorer survival.
|
23800698 |
2013 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The clinicopathological features of high-grade serous ovarian carcinoma (HGS-OvCa) patients with GOF p53 mutations were evaluated according to a comprehensive somatic mutation profile comprised of whole exome sequencing, mRNA expression, and protein expression profiles obtained from the Cancer Genome Atlas (TCGA).
|
23967324 |
2013 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our data indicate that parallel expression of MMP-2 epithelial/stromal cells and p53 may enhance cells invasion and metastasis in ovarian carcinoma.
|
23915071 |
2013 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.
|
21552211 |
2011 |
Ovarian Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Studies on the p53 expression and outcome for women with ovarian carcinoma have produced conflicting results.
|
20629008 |
2010 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In this study we show that curcumin exhibited time- and dose-dependent cytotoxicity against monolayer cultures of ovarian carcinoma cell lines with differing p53 status (wild-type p53: HEY, OVCA429; mutant p53: OCC1; null p53: SKOV3).
|
19676105 |
2010 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our study provides evidence that both germ line and somatic alterations of the p53 pathway influence the incidence and survival of ovarian carcinoma, and it underscores the importance of assessing the functionality of p53 in order to predict the sensitivity of platinum-based chemotherapies and patient outcome.
|
18172257 |
2008 |
Ovarian Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Conditional suppression of functional p53 increased p110alpha transcripts, protein levels and PI3K activity in immortalized, non-tumorigenic ovarian surface epithelial (OSE) cells, the precursors of ovarian carcinoma.
|
18270270 |
2008 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Determining p53 mutational status can be useful in predicting therapeutic response to drugs in ovarian carcinoma, especially in non-serous tumors.
|
16459017 |
2006 |
Ovarian Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Analysis of EphA2 expression and mutant p53 in ovarian carcinoma.
|
16969087 |
2006 |